The class Ic/IVb antiarrhythmic drug flecainide has emerged as an effective alternative in patients with catecholaminergic polymorphic ventricular tachycardia, a genetic arrhythmic disorder of RYR2 hyperactivity.[27, 28, 29] The hyperactive RYR2 phenotype in ARVC iPSC‐CMs prompted us to investigate whether flecainide could suppress the impact of TMEM43‐P386S in ARVC iPSC‐CMs. This evidence concerns the gene RYR2 and Arrhythmogenic right ventricular dysplasia.